Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision

As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.